JPMorgan Chase & Co. Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its price target reduced by investment analysts at JPMorgan Chase & Co. from $120.00 to $118.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the healthcare product maker’s stock. JPMorgan Chase & Co.’s target price points to a potential upside of 17.32% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. Piper Sandler reiterated an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Citigroup upped their price target on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday, July 17th. Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 18th. Robert W. Baird raised their price target on shares of Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Wells Fargo & Company lifted their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $117.84.

Abbott Laboratories Stock Up 0.1%

Shares of NYSE:ABT traded up $0.07 on Thursday, hitting $100.58. 742,079 shares of the company traded hands, compared to its average volume of 11,279,271. The stock has a 50 day simple moving average of $105.47 and a 200-day simple moving average of $98.28. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a market cap of $174.04 billion, a PE ratio of 32.40, a PEG ratio of 1.90 and a beta of 0.59. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.42. The company had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.30 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.53 earnings per share for the current year.

Institutional Trading of Abbott Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Manning & Napier Advisors LLC bought a new position in Abbott Laboratories in the second quarter worth approximately $31,000. Summit Securities Group LLC grew its position in shares of Abbott Laboratories by 41.3% during the 2nd quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock valued at $37,000 after acquiring an additional 118 shares during the period. Addison Advisors LLC bought a new stake in shares of Abbott Laboratories during the 2nd quarter valued at $40,000. E Fund Management Hong Kong Co. Ltd. increased its stake in shares of Abbott Laboratories by 221.6% in the 2nd quarter. E Fund Management Hong Kong Co. Ltd. now owns 476 shares of the healthcare product maker’s stock worth $43,000 after purchasing an additional 328 shares in the last quarter. Finally, Allied Private Wealth LLC purchased a new stake in shares of Abbott Laboratories in the 2nd quarter worth $45,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted earnings of $1.42 per share, in line with the broader consensus, while revenue of $13.01 billion slightly exceeded the $12.99 billion estimate. Reported sales increased 14.5% year over year, and comparable sales rose 7%. Abbott Reports Third-Quarter 2026 Results
• Positive Sentiment: The company reaffirmed its full-year adjusted EPS guidance, while highlighting new product approvals and margin expansion. The results also showed year-over-year EPS growth from $1.30 to $1.42. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
• Positive Sentiment: Robert W. Baird raised its ABT price target from $121 to $123 and maintained an “outperform” rating. BTIG lowered its target from $134 to $125 but retained a “buy” rating; both targets imply substantial upside from the reference price. Benzinga Analyst Actions
• Neutral Sentiment: Abbott intends to execute a tax-free spin-off of its approximately $8.5 billion Nutrition business, including Similac, Ensure and Pedialyte, by the end of 2027. Management expects the separation to sharpen strategic focus and improve Abbott’s growth and margin profile, but investors must assess execution and the eventual standalone businesses. Abbott Nutrition Spin-Off Announcement
• Negative Sentiment: Abbott reduced its 2026 sales-growth forecast, citing weakness in medical devices. That outlook revision overshadowed the revenue beat and raised concerns about near-term momentum. Abbott Lowers 2026 Sales Growth Forecast
• Negative Sentiment: Some analysts characterized adjusted EPS as a modest miss against a $1.43 estimate, adding to the cautious reaction. The Nutrition separation also introduced uncertainty and contributed to selling pressure despite strong headline growth. ABT Stock Down After Third-Quarter Results

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.